S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:FHTX

Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

$6.71
+0.43 (+6.85%)
(As of 03/28/2024 ET)
Today's Range
$6.26
$6.76
50-Day Range
$2.82
$7.94
52-Week Range
$2.70
$9.97
Volume
68,593 shs
Average Volume
99,895 shs
Market Capitalization
$285.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.80

Foghorn Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
135.5% Upside
$15.80 Price Target
Short Interest
Bearish
6.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Foghorn Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.05) to ($1.61) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.67 out of 5 stars

Medical Sector

725th out of 939 stocks

Pharmaceutical Preparations Industry

345th out of 444 stocks

FHTX stock logo

About Foghorn Therapeutics Stock (NASDAQ:FHTX)

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FHTX Stock Price History

FHTX Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Foghorn Therapeutics: Q4 Earnings Insights
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc (FHTX)
Foghorn Therapeutics Announces CFO Departure
Foghorn Therapeutics Inc Ordinary Shares FHTX
See More Headlines
Receive FHTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/29/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FHTX
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.80
High Stock Price Target
$20.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+135.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-98,430,000.00
Net Margins
-288.17%
Pretax Margin
-275.80%

Debt

Sales & Book Value

Annual Sales
$34.15 million
Book Value
($1.83) per share

Miscellaneous

Free Float
38,637,000
Market Cap
$285.64 million
Optionable
Optionable
Beta
3.17
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Adrian H. B. Gottschalk (Age 48)
    President, CEO & Director
    Comp: $784.65k
  • Dr. Steven F. Bellon Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $572.6k
  • Dr. Alfonso Quintas Cardama M.D. (Age 52)
    Chief Medical Officer
    Comp: $300.16k
  • Dr. Gerald R. Crabtree M.d.
    Founder & Member of Scientific Advisory Board
  • Mr. Stephen J. DiPalma (Age 65)
    Treasurer & Interim CFO
  • Ms. Karin Hellsvik
    VP, Corporate Affairs & Investor Relations
  • Mr. Michael J. LaCascia (Age 59)
    Chief Legal Officer
    Comp: $565.5k
  • Mr. Saurabh Sewak Ph.D.
    Vice President of Corporate Development
  • Mr. Carlos Costa (Age 50)
    Chief People Officer
  • Ms. Fanny Cavalie (Age 46)
    Chief Strategy & Business Operations Officer

FHTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Foghorn Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FHTX shares.
View FHTX analyst ratings
or view top-rated stocks.

What is Foghorn Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1 year price objectives for Foghorn Therapeutics' stock. Their FHTX share price targets range from $6.00 to $20.00. On average, they anticipate the company's stock price to reach $15.80 in the next year. This suggests a possible upside of 135.5% from the stock's current price.
View analysts price targets for FHTX
or view top-rated stocks among Wall Street analysts.

How have FHTX shares performed in 2024?

Foghorn Therapeutics' stock was trading at $6.45 at the start of the year. Since then, FHTX stock has increased by 4.0% and is now trading at $6.71.
View the best growth stocks for 2024 here
.

When is Foghorn Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our FHTX earnings forecast
.

How were Foghorn Therapeutics' earnings last quarter?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) released its earnings results on Thursday, March, 7th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.22. The company had revenue of $5.77 million for the quarter, compared to analyst estimates of $4.91 million.

What ETF holds Foghorn Therapeutics' stock?

Range Cancer Therapeutics ETF holds 14,641 shares of FHTX stock, representing 1.36% of its portfolio.

When did Foghorn Therapeutics IPO?

Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Foghorn Therapeutics' major shareholders?

Foghorn Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Raymond James & Associates (4.90%), Vanguard Group Inc. (2.43%), Vanguard Group Inc. (2.41%), Point72 Asset Management L.P. (1.28%), Birchview Capital LP (0.76%) and Northern Trust Corp (0.47%).
View institutional ownership trends
.

How do I buy shares of Foghorn Therapeutics?

Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FHTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners